Abpro Holdings, Inc. (ABPO)
OTCMKTS · Delayed Price · Currency is USD
0.1298
-0.0162 (-11.10%)
At close: Feb 27, 2026
Abpro Holdings Revenue
In the year 2024, Abpro Holdings had annual revenue of $183.00K with 50.00% growth.
Revenue
183.00K
Revenue Growth
+50.00%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
352.57K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 183.00K | 61.00K | 50.00% |
| Dec 31, 2023 | 122.00K | -1.91M | -93.99% |
| Dec 31, 2022 | 2.03M | 1.55M | 322.71% |
| Dec 31, 2021 | 480.00K | -1.72M | -78.19% |
| Dec 31, 2017 | 2.20M | 516.00K | 30.62% |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mesa Home Resources | 12.10M |
| Lancer Orthodontics | 6.19M |
| Landbay | 721.33K |
| AppSwarm | 196.33K |
| Zann Corp. | 481.00 |
| VGTel | -9.10K |
Abpro Holdings News
- 6 weeks ago - Abpro's Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72 - GlobeNewsWire
- 2 months ago - Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers - GlobeNewsWire
- 2 months ago - Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives - GlobeNewsWire
- 4 months ago - Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager - GlobeNewsWire
- 4 months ago - Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025 - GlobeNewsWire
- 11 months ago - Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager - GlobeNewsWire
- 1 year ago - Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025 - GlobeNewsWire